When was half life source released full#
When was half life source released trial#

When was half life source released trial#

The half-life extended format of IMA402 confers a serum half-life of >1 week in mice suggesting a favorable dosing regimen and prolonged drug exposure at therapeutic levels when compared to TCR Bispecifics lacking half-life extension strategiesĬlinical trial evaluating IMA402 in patients with solid tumors to start in 2023.In vitro safety assessment including toxicity screening against 20 normal tissue types, whole blood cytokine release assessment and alloreactivity evaluation confirmed favorable safety profile for IMA402.Sufficiently high drug doses were key to achieving the desired anti-tumor effects over a prolonged period

In vivo studies in mice demonstrated dose-dependent anti-tumor activity of IMA402.

IMA402 showed potent and selective activity against PRAME-positive tumor cell lines in vitro.

The IMA402 TCER ® is optimized to reduce T cell engager-associated toxicities in patients, which is demonstrated by reduced recruiter-mediated cytokine release in vitro.

The T cell recruiter domain is a proprietary low-affinity T cell recruiter against the TCR/CD3 complex that demonstrates superior in vivo tumor control compared to analogous TCER ® molecules designed with higher-affinity variants of a widely used antibody recruiter.

The IMA402 TCER ® utilizes a high-affinity TCR designed to specifically bind to an HLA-A*02:01-presented peptide derived from PRAME on tumor cells.

TCER ® format is optimized for efficacy and safety Immatics TCER ® molecules are 'off-the-shelf' TCR Bispecifics engineered with two binding regions: a TCR domain and a T cell recruiter domain.ġ) Clinical Trial Application (CTA) is the equivalent of an Investigational New Drug (IND) application in Europe The data are available as an ePoster on the ESMO platform at 9 AM on Saturday, September 10, and will be presented during the poster session from noon to 1 PM CEST on Monday, September 12.

IMA402 is the company’s second program in its TCR Bispecifics pipeline and is directed against an HLA-A*02:01-presented peptide derived from PRAME, a cancer target broadly expressed in many solid tumors. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a comprehensive preclinical data set for its T cell engaging receptor (TCER®) product candidate IMA402 at the European Society for Medical Oncology (ESMO) Congress 2022 held in Paris, France, from September 9 to 13, 2022.

Tuebingen, Germany and Houston, Texas, September 1 0, 2022 – Immatics N.V.

Phase 1/2 clinical trial on track to start in 2023 submission of the CTA/IND 1 application is planned for 2Q 2023.

When was half life source released full#

IMA402 is part of Immatics’ strategy to leverage the full clinical potential of targeting PRAME, one of the most promising targets for TCR-based therapies.

Pharmacokinetic characteristics of half-life extended IMA402 suggest potential for a favorable dosing regimen in patients with prolonged drug exposure at therapeutic levels.

In preclinical studies, IMA402 demonstrated enhanced anti-tumor activity in vivo and reduced T cell engager-associated toxicities as part of overall favorable in vitro safety profile.

TCER ® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME.